[go: up one dir, main page]

PE20241621A1 - Composiciones de polinucleotidos y sus usos - Google Patents

Composiciones de polinucleotidos y sus usos

Info

Publication number
PE20241621A1
PE20241621A1 PE2024001399A PE2024001399A PE20241621A1 PE 20241621 A1 PE20241621 A1 PE 20241621A1 PE 2024001399 A PE2024001399 A PE 2024001399A PE 2024001399 A PE2024001399 A PE 2024001399A PE 20241621 A1 PE20241621 A1 PE 20241621A1
Authority
PE
Peru
Prior art keywords
rna
molecule
ribonucleic acid
polynucleotide
fimh polypeptide
Prior art date
Application number
PE2024001399A
Other languages
English (en)
Inventor
Ye Che
Laurent Olivier Chorro
Fernando Martin Diaz
Robert George Konrad Donald
Jin Li
De Monerri Natalie Clare Silmon
Raphael Simon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20241621A1 publication Critical patent/PE20241621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a una molecula de polinucleotido de acido ribonucleico (ARN) que comprende al menos un marco abierto de lectura (ORF) que codifica un polipeptido antigenico de FimH; en donde el polipeptido de FimH tiene al menos un 90 %, 95, 96 %, 97 %, 98 % o 99 % de identidad con la secuencia de aminoacidos seleccionada entre SEQ ID NO: 1 a 64. En donde el ARN esta fusionado a un dominio dirigido a la membrana del extremo C-terminal por un enlazador. Una composicion que comprende la molecula de ARN, en la que la molecula de ARN esta formulada en una nanoparticula lipidica (ARN-LNP). Tambien se refiere a un metodo para inducir la respuesta inmune contra la infeccion por E. coli, la fabricacion de vacunas de acido ribonucleico que comprenden moleculas de polinucleotidos, y su uso en el tratamiento o prevencion de infeccion del tracto urinario.
PE2024001399A 2021-12-17 2022-12-14 Composiciones de polinucleotidos y sus usos PE20241621A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290895P 2021-12-17 2021-12-17
US202263384607P 2022-11-22 2022-11-22
PCT/IB2022/062232 WO2023111907A1 (en) 2021-12-17 2022-12-14 Polynucleotide compositions and uses thereof

Publications (1)

Publication Number Publication Date
PE20241621A1 true PE20241621A1 (es) 2024-08-07

Family

ID=84602480

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001399A PE20241621A1 (es) 2021-12-17 2022-12-14 Composiciones de polinucleotidos y sus usos

Country Status (10)

Country Link
EP (1) EP4448002A1 (es)
JP (1) JP2025503423A (es)
KR (1) KR20240116841A (es)
AU (1) AU2022410694A1 (es)
CA (1) CA3242476A1 (es)
CO (1) CO2024007519A2 (es)
IL (1) IL313494A (es)
MX (1) MX2024007522A (es)
PE (1) PE20241621A1 (es)
WO (1) WO2023111907A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4531902A1 (en) * 2022-05-25 2025-04-09 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024256962A1 (en) 2023-06-14 2024-12-19 Pfizer Inc. Method for stabilizing rna
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025202834A1 (en) 2024-03-26 2025-10-02 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
EP1333858B8 (en) 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
WO2007012191A1 (en) 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
IL298516B2 (en) 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
US9814769B2 (en) * 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
WO2016183501A1 (en) 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
AU2020205717B2 (en) 2019-01-11 2025-09-11 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4076647A1 (en) * 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
ES2987890T3 (es) * 2020-01-16 2024-11-18 Janssen Pharmaceuticals Inc Mutante de FimH, composiciones con el mismo y uso del mismo
CN115605498A (zh) * 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
KR20230117166A (ko) * 2020-12-02 2023-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 공여자 가닥 보완된 FimH
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR102746713B1 (ko) * 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도

Also Published As

Publication number Publication date
KR20240116841A (ko) 2024-07-30
JP2025503423A (ja) 2025-02-04
CA3242476A1 (en) 2023-06-22
EP4448002A1 (en) 2024-10-23
WO2023111907A1 (en) 2023-06-22
MX2024007522A (es) 2024-07-04
IL313494A (en) 2024-08-01
CO2024007519A2 (es) 2024-06-27
AU2022410694A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
PE20241621A1 (es) Composiciones de polinucleotidos y sus usos
RU2735101C2 (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
CU22302A1 (es) Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
Yadav et al. Characterization of immune response elicited by the recombinant outer membrane protein OmpF of Aeromonas hydrophila, a potential vaccine candidate in murine model
Bacelo et al. Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis
JPH04506005A (ja) 破傷風トキシンフラグメントｃの発現
CN101646772A (zh) 抗伤寒沙门氏菌和其它肠细菌病原体的基于番木瓜花叶病毒的疫苗
WO2010050903A1 (en) Chimeric flagellins for vaccines
JP3072345B1 (ja) 豚丹毒菌の組換えサブユニットワクチン
Liu et al. Identification and analysis of a Sciaenops ocellatus ISG15 homologue that is involved in host immune defense against bacterial infection
ES2581981T3 (es) Polipéptidos de Streptococcus suis y polinucleótidos codificantes de los mismos y su utilización en aplicaciones vacunales y diagnósticas
CN111856006A (zh) 牛支原体分泌蛋白MbovP274的应用
US12239696B2 (en) Chimeric vaccine antigens for anaplasmosis
WO2013144579A1 (en) Use of flagellin as a vaccine
CN103874502B (zh) 用于控制病原体的氨基酸序列
CN104250304A (zh) 一种融合蛋白及其编码的疫苗组合物与应用
KR100854594B1 (ko) 톨-유사 수용체-5 자극 활성이 강화된 ｐａｓ-플라젤린융합 단백질
CA2707684C (en) Novel exoenzyme toxin of aeromonas salmonicida, and uses therefor
AR132957A1 (es) Composiciones de polinucleótidos y usos de estas
Vasserman et al. Genetic detoxification and adjuvant-activity retention of Escherichia coli enterotoxin LT
AR133808A1 (es) Composiciones inmunogénicas contra la influenza
DK1913020T3 (da) Immunogene konstrukter
Sobhan et al. Molecular characterization and functional analysis of the PilQ380-705: a novel secretin domain in Pseudomonas aeruginosa
Gauci et al. Genes encoding homologous antigens in taeniid cestode parasites: Implications for development of recombinant vaccines produced in Escherichia coli
ZAKI et al. EXPRESSION OF MURINE POLYOMAVIRUS-LIKE PARTICLES WITH FIMBRIAL PROTEIN OF Pasteurella multocida.